1445349-99-4

Usage

Uses

Used in Pharmaceutical Industry:
PGA1 is used as a therapeutic agent for its anti-inflammatory and immunosuppressive properties. It is particularly effective in treating autoimmune diseases, inflammatory disorders, and cancer. PGA1 inhibits the production of pro-inflammatory cytokines, suppresses T-cell proliferation, and induces apoptosis in cancer cells.
Used in Cardiovascular Medicine:
PGA1 is used as a vasodilator and smooth muscle relaxant in the treatment of cardiovascular diseases. Its properties make it useful in managing conditions such as hypertension, atherosclerosis, and other related disorders.
Overall, PGA1 demonstrates potential as a versatile drug candidate for a wide range of medical applications, including the treatment of inflammatory conditions, autoimmune diseases, cancer, and cardiovascular diseases.

Upstream product

• 377078-56-3 C₂₈H₃₂O₅ 
• 377078-55-2 C₂₈H₃₄O₅ 
• 1044519-32-5 (-)-tert-butyl (5R,6E,8β,9β,11β,14Z)-5,9,11-trihydroxyprosta-6,14-dien-1-oate 
• 1044519-39-2 (-)-tert-butyl (5S,6E,8β,9β,11β,14Z)-5,9,11-trihydroxyprosta-6,14-dien-1-oate 
• 1025719-34-9 methyl (S,E)-7-{(1R,2S,3S,5R)-3,5-bis(tert-butyldimethylsilyloxy)-2-[(Z)-oct-2-enyl]cyclopentyl}-5-(tert-butyldimethylsilyloxy)hept-6-enoate 
• 249935-18-0 (E)-7-[(1R,2S,3S,5R)-5-Acetoxy-3-hydroxy-2-((Z)-oct-2-enyl)-cyclopentyl]-5-oxo-hept-6-enoic acid ethyl ester 
• 249935-16-8 (E)-7-[(1R,2S,3S,5R)-3,5-Dihydroxy-2-((Z)-oct-2-enyl)-cyclopentyl]-5-hydroxy-hept-6-enoic acid ethyl ester 
• 249935-17-9 (E)-7-[(1R,2S,3S,5R)-3,5-Dihydroxy-2-((Z)-oct-2-enyl)-cyclopentyl]-5-oxo-hept-6-enoic acid ethyl ester 
• 249935-35-1 (E)-(S)-7-[(1R,2S,3S,5R)-5-Acetoxy-3-hydroxy-2-((Z)-oct-2-enyl)-cyclopentyl]-5-hydroxy-hept-6-enoic acid ethyl ester 
• 1025719-76-9 methyl (R,E)-7-{(1R,2S,3S,5R)-3,5-bis(tert-butyldimethylsilyloxy)-2-[(Z)-oct-2-enyl]cyclopentyl}-5-(tert-butyldimethylsilyloxy)hept-6-enoate 
• 249935-36-2 (E)-(R)-7-[(1R,2S,3S,5R)-5-Acetoxy-3-hydroxy-2-((Z)-oct-2-enyl)-cyclopentyl]-5-hydroxy-hept-6-enoic acid ethyl ester 
• 1025719-78-1 methyl (R,E)-7-{(1S,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-[(Z)-oct-2-enyl]cyclopentyl}-5-(tert-butyldimethylsilyloxy)hept-6-enoate 
• 249935-23-7 (E)-7-[(1S,2R,3R,5S)-3-Acetoxy-5-hydroxy-2-((Z)-oct-2-enyl)-cyclopentyl]-5-oxo-hept-6-enoic acid ethyl ester 
• 377078-52-9 C₄₂H₇₂O₃Si₃ 

Relevant academic research and scientific papers

A cross-metathesis route to the 5-F2-isoprostanes

(Chemical Equation Presented) A library of eight 5-F2- isoprostanes was prepared through a ring-opening metathesis/cross-metathesis protocol between functionalized bicyclo[3.2.0]heptenes, ethylene, and α,β-unsaturated ketones. This sequence provided racemic enones in a regio- and stereoselective fashion that could be converted to enantiomerically enriched allylic alcohols through a catalyst-controlled asymmetric reduction. Completion of the sidechains, followed by global deprotection, resulted in a stereodivergent route to eight enantiomerically enriched 5-F2 isoprostanes. Overall, the synthesis of this library of known and anticipated lipid oxidation metabolites was achieved in 10 steps from commercially available 4-hydroxy-2-cyclopentenone.

Stereoselective synthesis of a cis-1,2-dialkylcyclopentane building block and its application in isoprostane synthesis (5-ent-F2c-IsoP)

The all-cis substituted cyclopentane 3a, an analogue of the Corey lactone, has been prepared from a readily available nortricyclanone derivative by a five-step sequence in an overall yield of 34%. This chiral building block has been applied in total syntheses of two diastereomeric isoprostanes belonging to the 5-F2 family: ent-5-F2c-IsoP (ent-1) and 5-epient-5-F2c-IsoP (ent-2). Key features of the syntheses are the introduction of the two unsaturated alkyl side chains through an E-selective Horner-Wadsworth-Emmons reaction with the base-sensitive syn-aldehyde 10, along with a Z-selective Wittig olefination. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Syntheses and preliminary pharmacological evaluation of the two epimers of the 5-F2t-isoprostane

The total synthesis of the 5-F2t-isoprostane 1 and its 5-epimer 2 from diacetone-D-glucose is described. We report preliminary data on the vascular properties of these compounds.

5-F2t-isoprostane, a human hormone?

Syntheses of the four enantiomerically pure diastereomers of 5-F2t-isoprostane (5-8) are described. The key step is the lipase-catalyzed chemo-enzymatic resolution of the racemic diol 40 to give the mono-acetates 41 and 42. The enantiomerically

Total synthesis of a novel isoprostane IPF(2α)-I and its identification in biological fluids

The first tokai synthesis of IPF(2α)-I 25 is described using D-glucose as starting material. This novel isoprostane has been used to establish its presence in human urine.